Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Growth Hormone Deficiency Companies

Several pharmaceutical companies are involved in the research, development, and production of treatments for growth hormone deficiency (GHD), a medical condition characterized by inadequate production of growth hormone by the pituitary gland.

Growth Hormone Deficiency Key Companies *Disclaimer: List of key companies in no particular orderLatest growth hormone deficiency Companies Update

June 2023: The therapy for growth hormone insufficiency in children, developed by Pfizer Inc and OPKO Health Inc, has been granted approval by the U.S. Food and Drug Administration. The clearance, after to an earlier rejection by the FDA in January of the previous year, resulted in a little increase in Pfizer's shares and a roughly 19% rise in Opko Health's shares during premarket trading. The approval has been granted for the administration of a hormone therapy, which may be administered through injection. This medication, marketed under the brand name Ngenla, has been authorized for the purpose of treating pediatric patients who are three years of age or older. It is anticipated that Ngenla will be made accessible in the United States by August. For an extended period, the administration of daily injections of growth hormones has been considered the prevailing approach in medical practice.

September 2023:

Ascendis Pharma A/S disclosed the findings of the enliGHten trial, an open-label extension study conducted to assess the enduring safety and effectiveness of TransCon hGH as a weekly therapeutic regimen for pediatric and adolescent patients diagnosed with growth hormone deficit (GHD). The enliGHten trial had a total of 298 individuals, with an average age of 10.3 years. The participants in these clinical studies were administered TransCon hGH for a maximum duration of 6 years. Furthermore, the findings of this study provide evidence that the achievement of long-term treatment objectives can be effectively and securely accomplished with the administration of TransCon hGH on a weekly basis.List of growth hormone deficiency Key companies in the market

Anhui Anke Biotechnology (Group) Co. Ltd.

Pfizer Inc.

Genetech Inc.

Biopartners GmbH

Lifetech Labs

Zhongshan Hygene Biopharm Co. Ltd.

Novo Nordisk A/S

Eli Lily and Company

Ipsen S.A.

Growth Hormone Deficiency Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.